To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective payment system, as provided under section 632(b)(1) of the American Taxpayer Relief Act of 2012.

Bill: 113-hr-413
Sponsor: full_name: Rep. Welch, Peter [D-VT-At Large]
Introduced: 2013-01-23
Policy area: Health
Subjects: Digestive and metabolic diseases

Drug therapy

Health care coverage and access

Medicaid

Prescription drugs
Latest action: action_date: 2013-02-08
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2013-01-23
action_desc: Introduced in House
text: <p>Amends the American Taxpayer Relief Act of 2012 to eliminate the two-year delay (until January 1, 2016) of the authority of the Secretary of Health and Human Services (HHS) to implement oral-only End Stage Renal Disease (ESRD)-related drugs in the ESRD prospective payment system (PPS) under title XVIII (Medicare) of the Social Security Act. (Thus authorizes the Secretary to implement such drugs in the ESRD-PPS immediately.)</p>

tv_txt: I 113th CONGRESS 1st Session H. R. 413 IN THE HOUSE OF REPRESENTATIVES January 23, 2013 Mr. Welch (for himself, Mr. Hanna , Mr. Cooper , and Mr. Braley of Iowa ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To eliminate the 2-year delay in including oral-only ESRD-related drugs in the Medicare ESRD prospective payment system, as provided under section 632(b)(1) of the American Taxpayer Relief Act of 2012.

1. Eliminating the 2-year delay in implementation of oral-only ESRD-related drugs in the Medicare ESRD prospective payment system Section 632(b) of the American Taxpayer Relief Act of 2012 ( Public Law 112–240 ) is amended by striking all that precedes With respect to the implementation and inserting the following:: (b) Monitoring of implementation of oral-Only ESRD-Related drugs in the ESRD prospective payment system With respect to the implementation .